## Won-Jung Koh

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4672626/publications.pdf

Version: 2024-02-01

379 papers

15,035 citations

18482 62 h-index 101 g-index

382 all docs 382 docs citations

times ranked

382

10747 citing authors

#	Article	IF	CITATIONS
1	Delamanid for Multidrug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine, 2012, 366, 2151-2160.	27.0	667
2	Clinical Significance of Differentiation of <i>Mycobacterium massiliense</i> from <i>Mycobacterium abscessus</i> American Journal of Respiratory and Critical Care Medicine, 2011, 183, 405-410.	5.6	464
3	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	13.7	452
4	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
5	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. European Respiratory Journal, 2012, 40, 1430-1442.	6.7	346
6	Antibiotic Treatment of <i>Mycobacterium abscessus</i> Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 896-902.	5.6	293
7	Update on pulmonary disease due to non-tuberculous mycobacteria. International Journal of Infectious Diseases, 2016, 45, 123-134.	3.3	267
8	Clinical Significance of Nontuberculous Mycobacteria Isolated From Respiratory Specimens in Korea. Chest, 2006, 129, 341-348.	0.8	255
9	Macrolide Treatment for <i>Mycobacterium abscessus</i> Infection and Inducible Resistance. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 917-925.	5.6	179
10	Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives. Tuberculosis and Respiratory Diseases, 2016, 79, 74.	1.8	172
11	Clinical Significance of the Differentiation Between Mycobacterium avium and Mycobacterium intracellulare in M avium Complex Lung Disease. Chest, 2012, 142, 1482-1488.	0.8	170
12	Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clinical Infectious Diseases, 2017, 64, 309-316.	5.8	169
13	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal, 2018, 51, 1800170.	6.7	159
14	Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1075-1082.	5.6	157
15	Outcomes of <i>Mycobacterium avium</i> complex lung disease based on clinical phenotype. European Respiratory Journal, 2017, 50, 1602503.	6.7	154
16	Nontuberculous Mycobacterial Pulmonary Infection in Immunocompetent Patients: Comparison of Thin-Section CT and Histopathologic Findings. Radiology, 2004, 231, 880-886.	7.3	151
17	Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis, 2007, 87, 551-556.	1.9	148
18	Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. International Journal of Infectious Diseases, 2010, 14, e479-e482.	3.3	143

#	Article	IF	CITATIONS
19	Treatment Outcomes for HIVâ€Uninfected Patients with Multidrugâ€Resistant and Extensively Drugâ€Resistant Tuberculosis. Clinical Infectious Diseases, 2008, 47, 496-502.	5.8	140
20	<i>Mycobacterium abscessus</i> pulmonary disease: individual patient data meta-analysis. European Respiratory Journal, 2019, 54, 1801991.	6.7	140
21	Intermittent Antibiotic Therapy for Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 96-103.	5.6	134
22	Bilateral Bronchiectasis and Bronchiolitis at Thin-Section CT: Diagnostic Implications in Nontuberculous Mycobacterial Pulmonary Infection. Radiology, 2005, 235, 282-288.	7.3	123
23	Nontuberculous Mycobacteria—Overview. Microbiology Spectrum, 2017, 5, .	3.0	116
24	Prevalence of Gastroesophageal Reflux Disease in Patients With Nontuberculous Mycobacterial Lung Disease. Chest, 2007, 131, 1825-1830.	0.8	113
25	Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007–2016. Emerging Infectious Diseases, 2019, 25, 569-572.	4.3	113
26	Treatment Outcomes and Survival Based on Drug Resistance Patterns in Multidrug-resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 113-119.	5.6	110
27	Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Diseases: A Korean Perspective. Journal of Korean Medical Science, 2005, 20, 913.	2.5	93
28	Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Pulmonary Disease. Natural Course on Serial Computed Tomographic Scans. Annals of the American Thoracic Society, 2013, 10, 299-306.	3.2	93
29	Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 1503-1507.	3.0	90
30	Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 6758-6765.	3.2	90
31	Occult nodal metastasis in patients with nonâ€small cell lung cancer at clinical stage IA by PET/CT. Respirology, 2010, 15, 1179-1184.	2.3	89
32	Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Medical Mycology, 2013, 51, 811-817.	0.7	89
33	Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. European Respiratory Journal, 2020, 55, 1900798.	6.7	89
34	Tuberculous Otitis Media: A Clinical and Radiologic Analysis of 52 Patients. Laryngoscope, 2006, 116, 921-927.	2.0	88
35	Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2009, 64, 388-391.	3.0	88
36	Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease. Journal of Korean Medical Science, 2016, 31, 649.	2.5	86

#	Article	lF	Citations
37	Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	86
38	Treatment of Refractory Mycobacterium avium Complex Lung Disease with a Moxifloxacin-Containing Regimen. Antimicrobial Agents and Chemotherapy, 2013, 57, 2281-2285.	3.2	82
39	Clinical Features of Recently Diagnosed Pulmonary Paragonimiasis in Korea. Chest, 2005, 128, 1423-1430.	0.8	81
40	Pleuropulmonary Paragonimiasis: CT Findings in 31 Patients. American Journal of Roentgenology, 2005, 185, 616-621.	2.2	81
41	Nontuberculous Mycobacterial Pulmonary Diseases in Immunocompetent Patients. Korean Journal of Radiology, 2002, 3, 145.	3.4	80
42	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine, the, 2018, 6, 265-275.	10.7	80
43	Treatment of <i>Mycobacterium avium </i> Complex Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2019, 82, 15.	1.8	80
44	Treatment outcomes for patients with synchronous multiple primary non-small cell lung cancer. Lung Cancer, 2011, 73, 237-242.	2.0	79
45	Increasing Recovery of Nontuberculous Mycobacteria from Respiratory Specimens over a 10-Year Period in a Tertiary Referral Hospital in South Korea. Tuberculosis and Respiratory Diseases, 2013, 75, 199.	1.8	79
46	Therapeutic Drug Monitoring in the Treatment of <i>Mycobacterium avium</i> Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 797-802.	5.6	77
47	USE OF SILICONE STENTS IN THE MANAGEMENT OF TRACHEOBRONCHIAL STENOSIS DUE TO TUBERCULOSIS. Chest, 2005, 128, 326S.	0.8	<b>7</b> 5
48	Thoracic Actinomycosis: CT Features with Histopathologic Correlation. American Journal of Roentgenology, 2006, 186, 225-231.	2.2	75
49	Radiographic and CT Findings of Nontuberculous Mycobacterial Pulmonary Infection Caused by <i>Mycobacterium abscessus</i> . American Journal of Roentgenology, 2003, 181, 513-517.	2.2	73
50	Optimal Duration of IV and Oral Antibiotics in the Treatment of Thoracic Actinomycosis. Chest, 2005, 128, 2211-2217.	0.8	72
51	Enhanced Efficacy of Therapeutic Cancer Vaccines Produced by Co-Treatment with <i>Mycobacterium tuberculosis </i> Heparin-Binding Hemagglutinin, a Novel TLR4 Agonist. Cancer Research, 2011, 71, 2858-2870.	0.9	72
52	Six-month Therapy with Aerosolized Interferon-Î <sup>3</sup> for Refractory Multidrug-Resistant Pulmonary Tuberculosis. Journal of Korean Medical Science, 2004, 19, 167.	2.5	68
53	The Role of Chest CT Scanning in TB Outbreak Investigation. Chest, 2010, 137, 1057-1064.	0.8	68
54	Pulmonary Mycobacterial Disease: Diagnostic Performance of Low-Dose Digital Tomosynthesis as Compared with Chest Radiography. Radiology, 2010, 257, 269-277.	7.3	68

#	Article	IF	CITATIONS
55	Thin-Section CT Findings of Nontuberculous Mycobacterial Pulmonary Diseases: Comparison Between Mycobacterium avium-intracellulare Complex and Mycobacterium abscessus Infection. Journal of Korean Medical Science, 2005, 20, 777.	2.5	67
56	Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 858-864.	5 <b>.</b> 6	67
57	Mycobacterial Genotypes Are Associated With Clinical Manifestation and Progression of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. Clinical Infectious Diseases, 2013, 57, 32-39.	5 <b>.</b> 8	67
58	Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respiratory Medicine, 2008, 102, 437-442.	2.9	66
59	Surgical Treatment for Multidrug-Resistant and Extensive Drug-Resistant Tuberculosis. Annals of Thoracic Surgery, 2010, 89, 1597-1602.	1.3	66
60	Serial CT Findings of <i>Mycobacterium massiliense </i> Pulmonary Disease Compared with <i>Mycobacterium abscessus </i> Disease after Treatment with Antibiotic Therapy. Radiology, 2012, 263, 260-270.	7.3	65
61	NRAMP1 Gene Polymorphism and Susceptibility to Nontuberculous Mycobacterial Lung Diseases. Chest, 2005, 128, 94-101.	0.8	64
62	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clinical Infectious Diseases, 2016, 62, 887-895.	5.8	64
63	Inactive Hepatitis B Surface Antigen Carrier State and Hepatotoxicity During Antituberculosis Chemotherapy <xref rid="AFF1">&lt;<sup>*</sup>. Chest, 2005, 127, 1304.</xref>	0.8	64
64	Hypothesis on the Evolution of Cavitary Lesions in Nontuberculous Mycobacterial Pulmonary Infection: Thin-Section CT and Histopathologic Correlation. American Journal of Roentgenology, 2005, 184, 1247-1252.	2.2	63
65	Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. Respiratory Medicine, 2010, 104, 1729-1735.	2.9	62
66	Prognostic factors and causes of death in Korean patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2006, 100, 451-457.	2.9	61
67	Efficient Differentiation of <i>Mycobacterium avium </i> Complex Species and Subspecies by Use of Five-Target Multiplex PCR. Journal of Clinical Microbiology, 2010, 48, 4057-4062.	3.9	61
68	The Drug Resistance Profile of <i>Mycobacterium abscessus</i> Group Strains from Korea. Annals of Laboratory Medicine, 2014, 34, 31-37.	2.5	61
69	Comparison of drug resistance genotypes between Beijing and non-Beijing family strains of Mycobacterium tuberculosis in Korea. Journal of Microbiological Methods, 2005, 63, 165-172.	1.6	60
70	Rigid Bronchoscopic Intervention in Patients with Respiratory Failure Caused by Malignant Central Airway Obstruction. Journal of Thoracic Oncology, 2006, 1, 319-323.	1.1	60
71	Drug-sensitive tuberculosis, multidrug-resistant tuberculosis, and nontuberculous mycobacterial pulmonary disease in nonAIDS adults: comparisons of thin-section CT findings. European Radiology, 2006, 16, 1934-1941.	<b>4.</b> 5	59
72	Rifabutin Is Active against Mycobacterium abscessus in Mice. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	59

#	Article	IF	Citations
73	Treatment of thoracic actinomycosis: A retrospective analysis of 40 patients. Annals of Thoracic Medicine, 2010, 5, 80.	1.8	57
74	Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis. Journal of Infection, 2014, 68, 494-499.	3.3	56
75	Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infectious Diseases, 2015, 15, 76.	2.9	56
76	In Vitro Antimicrobial Susceptibility of Mycobacterium abscessus in Korea. Journal of Korean Medical Science, 2008, 23, 49.	2.5	55
77	The Genome Sequence of â€~Mycobacterium massiliense' Strain CIP 108297 Suggests the Independent Taxonomic Status of the Mycobacterium abscessus Complex at the Subspecies Level. PLoS ONE, 2013, 8, e81560.	2.5	54
78	Same meat, different gravy: ignore the new names of mycobacteria. European Respiratory Journal, 2019, 54, 1900795.	6.7	54
79	Prognostic factors in pulmonary tuberculosis requiring mechanical ventilation for acute respiratory failure. Respirology, 2007, 12, 406-411.	2.3	53
80	Decreased Cytokine Production in Patients with Nontuberculous Mycobacterial Lung Disease. Lung, 2007, 185, 337-341.	3.3	53
81	Performances of Prognostic Scoring Systems in Patients With Healthcare-Associated Pneumonia. Clinical Infectious Diseases, 2013, 56, 625-632.	5.8	52
82	Changing Epidemiology of Nontuberculous Mycobacterial Lung Diseases in a Tertiary Referral Hospital in Korea between 2001 and 2015. Journal of Korean Medical Science, 2018, 33, e65.	2.5	52
83	Radiological Findings of Extensively Drug-Resistant Pulmonary Tuberculosis in Non-AIDS Adults: Comparisons with Findings of Multidrug-Resistant and Drug-Sensitive Tuberculosis. Korean Journal of Radiology, 2009, 10, 207.	3.4	50
84	Repeated derecruitments accentuate lung injury during mechanical ventilation*. Critical Care Medicine, 2002, 30, 1848-1853.	0.9	49
85	Treatment outcomes of patients with adenoid cystic carcinoma of the airway. Lung Cancer, 2011, 72, 244-249.	2.0	48
86	Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. Chest, 2016, 150, 1211-1221.	0.8	48
87	Solitary Pulmonary Nodules Caused by Mycobacterium tuberculosis and Mycobacterium avium Complex. Lung, 2010, 188, 25-31.	3.3	46
88	Distribution of Nontuberculous Mycobacteria by Multigene Sequence-Based Typing and Clinical Significance of Isolated Strains. Journal of Clinical Microbiology, 2014, 52, 1207-1212.	3.9	46
89	Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. International Journal of Infectious Diseases, 2017, 60, 49-56.	3.3	46
90	Development of Macrolide Resistance and Reinfection in Refractory <i>Mycobacterium avium </i> Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1322-1330.	5.6	46

#	Article	IF	Citations
91	Association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and nontuberculous mycobacterial lung disease in a Korean population. Human Immunology, 2008, 69, 572-576.	2.4	45
92	Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2009, 33, 92-93.	2.5	45
93	Prognostic Value of 18F-FDG Uptake on Positron Emission Tomography in Patients with Pathologic Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1331-1336.	1.1	45
94	Impact of Diabetes on Treatment Outcomes and Long-Term Survival in Multidrug-Resistant Tuberculosis. Respiration, 2013, 86, 472-478.	2.6	45
95	Diagnosis of Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease in Korea. Tuberculosis and Respiratory Diseases, 2014, 77, 1.	1.8	45
96	High-Resolution CT Findings of <i>Mycobacterium avium-intracellulare</i> Complex Pulmonary Disease: Correlation with Pulmonary Function Test Results. American Journal of Roentgenology, 2008, 191, W160-W166.	2.2	44
97	Surgical Treatment of Pulmonary Diseases Due to Nontuberculous Mycobacteria. Journal of Korean Medical Science, 2008, 23, 397.	2.5	44
98	Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations. Annals of Laboratory Medicine, 2017, 37, 97-107.	2.5	44
99	<i>In Vitro</i> Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	44
100	Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	44
101	Lung function, coronary artery calcification, and metabolic syndrome in 4905 Korean males. Respiratory Medicine, 2010, 104, 1326-1335.	2.9	43
102	Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 6076-6083.	3.2	43
103	Development of a Prediction Rule for Estimating Postoperative Pulmonary Complications. PLoS ONE, 2014, 9, e113656.	2.5	43
104	Rigid Bronchoscopic Intervention in Patients with Respiratory Failure Caused by Malignant Central Airway Obstruction. Journal of Thoracic Oncology, 2006, 1, 319-323.	1.1	42
105	Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease. Chest, 2016, 150, 1222-1232.	0.8	42
106	Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease. PLoS ONE, 2017, 12, e0188716.	2.5	41
107	Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
108	Factors that Predict Negative Results of QuantiFERON-TB Gold In-Tube Test in Patients with Culture-Confirmed Tuberculosis: A Multicenter Retrospective Cohort Study. PLoS ONE, 2015, 10, e0129792.	2.5	40

#	Article	IF	CITATIONS
109	DAILY MEASUREMENT OF NASAL NITRIC OXIDE (NO) IN HEALTHY NON-SMOKERS AND TRACHEOTOMIZED MECHANICALLY VENTILATED PATIENTS. Chest, 2005, 128, 2211-7.	0.8	40
110	Clinical characteristics and efficacy of bronchoscopic intervention for tracheobronchial leiomyoma. Respirology, 2008, 13, 908-912.	2.3	39
111	Standardized Combination Antibiotic Treatment of Mycobacterium avium Complex Lung Disease. Yonsei Medical Journal, 2010, 51, 888.	2.2	39
112	Comparison of the Xpert MTB/RIF and Cobas TaqMan MTB Assays for Detection of Mycobacterium tuberculosis in Respiratory Specimens. Journal of Clinical Microbiology, 2013, 51, 3225-3227.	3.9	39
113	Genetic diversity of clinical Mycobacterium avium subsp. hominissuis and Mycobacterium intracellulare isolates causing pulmonary diseases recovered from different geographical regions. Infection, Genetics and Evolution, 2015, 36, 250-255.	2.3	39
114	Distribution and clinical significance of Mycobacterium avium complex species isolated from respiratory specimens. Diagnostic Microbiology and Infectious Disease, 2017, 88, 125-137.	1.8	39
115	Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Infection, Genetics and Evolution, 2019, 72, 169-182.	2.3	39
116	Hepatitis C Virus Infection and Hepatotoxicity During Antituberculosis Chemotherapy. Chest, 2007, 131, 803-808.	0.8	38
117	Activities of Moxifloxacin in Combination with Macrolides against Clinical Isolates of Mycobacterium abscessus and Mycobacterium massiliense. Antimicrobial Agents and Chemotherapy, 2012, 56, 3549-3555.	3.2	38
118	Rapid Diagnosis of Tuberculosis and Multidrug Resistance Using a MGIT 960 System. Annals of Laboratory Medicine, 2012, 32, 264-269.	2.5	38
119	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Diagnosis of Central Lung Parenchymal Lesions. Yonsei Medical Journal, 2013, 54, 672.	2.2	38
120	Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. Journal of Critical Care, 2014, 29, 356-361.	2.2	38
121	A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Design, Development and Therapy, 2015, 9, 5433.	4.3	38
122	Clinical Significance of Mycobacterium kansasii Isolates from Respiratory Specimens. PLoS ONE, 2015, 10, e0139621.	2.5	38
123	Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respiratory Medicine, 2019, 151, 1-7.	2.9	38
124	Nontuberculous mycobacteria isolated during the treatment of pulmonary tuberculosis. Respiratory Medicine, 2009, 103, 1936-1940.	2.9	37
125	Risk Factors for Death during Pulmonary Tuberculosis Treatment in Korea: A Multicenter Retrospective Cohort Study. Journal of Korean Medical Science, 2014, 29, 1226.	2.5	37
126	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. Journal of Clinical Microbiology, 2018, 56, .	3.9	37

#	Article	IF	CITATIONS
127	False-negative interferon- $\hat{I}^3$ release assay results in active tuberculosis: a TBNET study. European Respiratory Journal, 2015, 45, 279-283.	6.7	36
128	Clinical Characteristics and Treatment Outcomes of <i>Mycobacterium kansasii </i> Lung Disease in Korea. Yonsei Medical Journal, 2010, 51, 552.	2.2	35
129	Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. Journal of Infection and Chemotherapy, 2018, 24, 315-318.	1.7	35
130	Drug Resistance Rates of Mycobacterium tuberculosis at a Private Referral Center in Korea. Journal of Korean Medical Science, 2007, 22, 677.	2.5	34
131	Development and Application of Multiprobe Real-Time PCR Method Targeting the <i>hsp65</i> Gene for Differentiation of <i>Mycobacterium</i> Species from Isolates and Sputum Specimens. Journal of Clinical Microbiology, 2010, 48, 3073-3080.	3.9	34
132	Interferon- $\hat{l}^3$ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clinical Rheumatology, 2011, 30, 1535-1541.	2.2	34
133	Tuberculosis. Current Opinion in Pulmonary Medicine, 2014, 20, 280-286.	2.6	34
134	Clinical utility of the QuantiFERON-TB Gold In-Tube test for the diagnosis of active pulmonary tuberculosis. Scandinavian Journal of Infectious Diseases, 2009, 41, 818-822.	1.5	33
135	GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance. Journal of Clinical Microbiology, 2019, 57, .	3.9	33
136	Serodiagnosis of Mycobacterium avium Complex and Mycobacterium abscessus Complex Pulmonary Disease by Use of IgA Antibodies to Glycopeptidolipid Core Antigen. Journal of Clinical Microbiology, 2013, 51, 2747-2749.	3.9	32
137	Development of a One-Step Multiplex PCR Assay for Differential Detection of Major Mycobacterium Species. Journal of Clinical Microbiology, 2017, 55, 2736-2751.	3.9	32
138	Clinical and Laboratory Differences between Lymphocyte- and Neutrophil-Predominant Pleural Tuberculosis. PLoS ONE, 2016, 11, e0165428.	2.5	32
139	Recruitment maneuvers attenuate repeated derecruitment-associated lung injury. Critical Care Medicine, 2005, 33, 1070-1076.	0.9	31
140	Impaired expression of Toll-like receptor 2 in nontuberculous mycobacterial lung disease. European Respiratory Journal, 2007, 30, 736-742.	6.7	31
141	Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide capreomycin antibiotics in Korea. World Journal of Microbiology and Biotechnology, 2013, 29, 975-982.	3.6	31
142	Antibiotic treatment for nontuberculous mycobacterial lung disease. Expert Review of Respiratory Medicine, 2016, 10, 557-568.	2.5	31
143	Draft Genome Sequence of Mycobacterium abscessus subsp. bolletii BDT. Journal of Bacteriology, 2012, 194, 2756-2757.	2.2	30
144	Severe vitamin <scp>D</scp> deficiency is associated with nonâ€tuberculous mycobacterial lung disease: A caseâ€control study. Respirology, 2013, 18, 983-988.	2.3	30

#	Article	IF	Citations
145	Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes. Annals of the American Thoracic Society, 2016, 13, 364-370.	3.2	30
146	Pulmonary Nocardiosis with Multiple Cavitary Nodules in a HIV-Negative Immunocompromised Patient. Internal Medicine, 2004, 43, 852-854.	0.7	29
147	Serum cytokines and critical illness-related corticosteroid insufficiency. Intensive Care Medicine, 2010, 36, 1845-1851.	8.2	29
148	Bronchoscopic features and bronchoscopic intervention for endobronchial hamartoma. Respirology, 2010, 15, 150-154.	2.3	29
149	Efficient Differentiation of Mycobacterium abscessus Complex Isolates to the Species Level by a Novel PCR-Based Variable-Number Tandem-Repeat Assay. Journal of Clinical Microbiology, 2011, 49, 1107-1109.	3.9	29
150	The Incidence, Causes, and Prognostic Significance of New-Onset Thrombocytopenia in Intensive Care Units: A Prospective Cohort Study in a Korean Hospital. Journal of Korean Medical Science, 2012, 27, 1418.	2.5	29
151	Repeated Derecruitments Accentuate Lung Injury During Mechanical Ventilation*. Critical Care Medicine, 2013, 41, e423-e430.	0.9	29
152	Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. Diagnostic Microbiology and Infectious Disease, 2019, 93, 107-111.	1.8	29
153	Endobronchial Actinomycosis Associated with Broncholithiasis: CT Findings for Nine Patients. American Journal of Roentgenology, 2005, 185, 347-353.	2.2	28
154	Chronic Expanding Hematoma of the Thorax. Yonsei Medical Journal, 2007, 48, 337.	2.2	28
155	Serial CT Findings of Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Pulmonary Disease With Antibiotic Treatment. American Journal of Roentgenology, 2013, 201, 764-772.	2.2	28
156	Comparison of clinical characteristics in patients with Takayasu arteritis with and without concomitant tuberculosis. Heart and Vessels, 2016, 31, 1277-1284.	1.2	28
157	Evaluation of vitamin status in patients with pulmonary tuberculosis. Journal of Infection, 2017, 74, 272-280.	3.3	28
158	Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease. Diagnostic Microbiology and Infectious Disease, 2018, 90, 293-295.	1.8	28
159	Rigid bronchoscopic intervention in patients with respiratory failure caused by malignant central airway obstruction. Journal of Thoracic Oncology, 2006, 1, 319-23.	1.1	28
160	Natural stent in the management of postâ€intubation tracheal stenosis. Respirology, 2009, 14, 583-588.	2.3	27
161	Prognostic Factors for Endotracheal Silicone Stenting in the Management of Inoperable Post-Intubation Tracheal Stenosis. Yonsei Medical Journal, 2012, 53, 565.	2.2	27
162	Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27

#	Article	IF	Citations
163	Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. Leukemia and Lymphoma, 2008, 49, 1929-1934.	1.3	26
164	Nodal Stations and Diagnostic Performances of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients with Non-Small Cell Lung Cancer. Journal of Korean Medical Science, 2012, 27, 46.	2.5	26
165	Serum Concentrations of Trace Elements in Patients with Tuberculosis and Its Association with Treatment Outcome. Nutrients, 2015, 7, 5969-5981.	4.1	26
166	Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report. BMC Infectious Diseases, 2016, 16, 207.	2.9	26
167	Outcomes of Bronchial Artery Embolization for Life-Threatening Hemoptysis in Patients with Chronic Pulmonary Aspergillosis. PLoS ONE, 2016, 11, e0168373.	2.5	26
168	Clinical characteristics and treatment outcomes of pulmonary disease caused by Mycobacterium chimaera. Diagnostic Microbiology and Infectious Disease, 2016, 86, 382-384.	1.8	26
169	Functional status and mortality prediction in communityâ€acquired pneumonia. Respirology, 2017, 22, 1400-1406.	2.3	26
170	Diagnosis and Treatment of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists in Korea. Journal of Korean Medical Science, 2007, 22, 779.	2.5	25
171	The Role of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Diagnosis of Mediastinal and Hilar Lymph Node Metastases in Patients with Extrapulmonary Malignancy. Internal Medicine, 2011, 50, 2525-2532.	0.7	25
172	Usefulness of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Diagnosis of Sarcoidosis. Yonsei Medical Journal, 2013, 54, 1416.	2.2	25
173	Importance of Reciprocal Balance of T Cell Immunity in Mycobacterium abscessus Complex Lung Disease. PLoS ONE, 2014, 9, e109941.	2.5	25
174	QuantiFERON-TB Gold In-Tube Assay for Screening Arthritis Patients for Latent Tuberculosis Infection before Starting Anti-Tumor Necrosis Factor Treatment. PLoS ONE, 2015, 10, e0119260.	2.5	25
175	Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy, 2015, 70, 3127-3133.	3.0	25
176	A nonsense variant in <scp><i>NME5</i></scp> causes human primary ciliary dyskinesia with radial spoke defects. Clinical Genetics, 2020, 98, 64-68.	2.0	25
177	High virulent clinical isolates of Mycobacterium abscessus from patients with the upper lobe fibrocavitary form of pulmonary disease. Microbial Pathogenesis, 2009, 47, 321-328.	2.9	24
178	Factors predicting outcome following airway stenting for postâ€tuberculosis tracheobronchial stenosis. Respirology, 2011, 16, 959-964.	2.3	24
179	Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	24
180	Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates. Scientific Reports, 2021, 11, 6108.	3.3	24

#	Article	IF	Citations
181	Treatment of Isoniazid-Resistant Pulmonary Tuberculosis. Tuberculosis and Respiratory Diseases, 2020, 83, 20.	1.8	24
182	Toll-Like Receptor 2 Polymorphisms and Nontuberculous Mycobacterial Lung Diseases. Vaccine Journal, 2006, 13, 818-819.	3.1	23
183	Chest Radiographic Findings in Primary Pulmonary Tuberculosis: Observations from High School Outbreaks. Korean Journal of Radiology, 2010, 11, 612.	3.4	23
184	Association of CFTR gene variants with nontuberculous mycobacterial lung disease in a Korean population with a low prevalence of cystic fibrosis. Journal of Human Genetics, 2013, 58, 298-303.	2.3	23
185	Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. International Journal of COPD, 2016, 11, 23.	2.3	23
186	Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline. International Journal of COPD, 2016, Volume 11, 2757-2764.	2.3	23
187	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respiratory Medicine, 2020, 161, 105853.	2.9	23
188	Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers. Supportive Care in Cancer, 2013, 21, 1647-1653.	2.2	22
189	Serum inflammatory profiles in pulmonary tuberculosis and their association with treatment response. Journal of Proteomics, 2016, 149, 23-30.	2.4	21
190	Interferon- $\hat{l}^3$ release assay for tuberculosis screening of healthcare workers at a Korean tertiary hospital. Scandinavian Journal of Infectious Diseases, 2010, 42, 943-945.	1.5	20
191	Initial Lactate Level and Mortality in Septic Shock Patients with Hepatic Dysfunction. Anaesthesia and Intensive Care, 2011, 39, 862-867.	0.7	20
192	Clinical significance of a single isolation of pathogenic nontuberculous mycobacteria from sputum specimens. Diagnostic Microbiology and Infectious Disease, 2013, 75, 225-226.	1.8	20
193	Evaluation of the Cobas TaqMan MTB Test for the Detection of Mycobacterium tuberculosis Complex According to Acid-Fast-Bacillus Smear Grades in Respiratory Specimens. Journal of Clinical Microbiology, 2015, 53, 696-698.	3.9	20
194	A Novel Therapeutic Approach Using Mesenchymal Stem Cells to Protect Against <i>Mycobacterium abscessus</i> . Stem Cells, 2016, 34, 1957-1970.	3.2	20
195	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2017, 49, 1600993.	6.7	20
196	Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea. European Respiratory Journal, 2019, 54, 1900811.	6.7	20
197	A PEPTIDE WITH ANTI-TRANSGLUTAMINASE ACTIVITY DECREASES LIPOPOLYSACCHARIDE-INDUCED LUNG INFLAMMATION IN MICE. Experimental Lung Research, 2006, 32, 43-53.	1.2	19
198	Posttuberculosis Tracheobronchial Stenosis: Use of CT to Optimize the Time of Silicone Stent Removal. Radiology, 2012, 263, 562-568.	7.3	19

#	Article	IF	Citations
199	Classification of broncholiths and clinical outcomes. Respirology, 2013, 18, 637-642.	2.3	19
200	miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease. Scientific Reports, 2020, 10, 3178.	3.3	19
201	Routine screening by brain magnetic resonance imaging decreased the brain metastasis rate following surgery for lung adenocarcinoma. Lung Cancer, 2007, 58, 68-72.	2.0	18
202	Polymorphisms of interferonâ€Î³ and interferonâ€Î³ receptor 1 genes and pulmonary tuberculosis in Koreans. Respirology, 2007, 12, 906-910.	2.3	18
203	Pulmonary paragonimiasis mimicking lung cancer in a tertiary referral centre in Korea. International Journal of Tuberculosis and Lung Disease, 2011, 15, 674-679.	1.2	18
204	Mutations in <i>gyrA</i> and <i>gyrB</i> in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
205	Assessment of 7 trace elements in serum of patients with nontuberculous mycobacterial lung disease. Journal of Trace Elements in Medicine and Biology, 2019, 53, 84-90.	3.0	18
206	Acute Pneumonia and Empyema Caused by Mycobacterium Intracellulare. Internal Medicine, 2006, 45, 1007-1010.	0.7	17
207	Treatment of isoniazid-resistant pulmonary tuberculosis. BMC Infectious Diseases, 2008, 8, 6.	2.9	17
208	Long-Term Tolerance of Airway Silicone Stent in Patients With Post-Tuberculosis Tracheobronchial Stenosis. ASAIO Journal, 2012, 58, 530-534.	1.6	17
209	Timing of silicone stent removal in patients with post-tuberculosis bronchial stenosis. Annals of Thoracic Medicine, 2013, 8, 218.	1.8	17
210	Detection and Assessment of Clarithromycin Inducible Resistant Strains Among Korean <i>Mycobacterium abscessus </i> Clinical Strains: PCR Methods. Journal of Clinical Laboratory Analysis, 2014, 28, 409-414.	2.1	17
211	Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrobial Agents and Chemotherapy, 2015, 59, 4994-4996.	3.2	17
212	Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients. International Journal of COPD, 2016, Volume 11, 1857-1865.	2.3	17
213	Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 471-477.	3.2	17
214	Airflow limitation severity and postâ€operative pulmonary complications following extraâ€pulmonary surgery in <scp>COPD</scp> patients. Respirology, 2017, 22, 935-941.	2.3	17
215	Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis. International Journal of Infectious Diseases, 2017, 65, 135-141.	3.3	17
216	Progression of Tuberculous Pleurisy: From a Lymphocyte-Predominant Free-Flowing Effusion to a Neutrophil-Predominant Loculated Effusion. Tuberculosis and Respiratory Diseases, 2017, 80, 90.	1.8	17

#	Article	IF	CITATIONS
217	Subspecies-specific sequence detection for differentiation of Mycobacterium abscessus complex. Scientific Reports, 2020, 10, 16415.	3.3	17
218	Report of a Korean Patient with Cystic Fibrosis, Carrying Q98R and Q220X Mutations in the CFTR Gene. Journal of Korean Medical Science, 2006, 21, 563.	2.5	16
219	Bronchogenic Cyst Rupture and Pneumonia after Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A Case Report. Tuberculosis and Respiratory Diseases, 2013, 74, 177.	1.8	16
220	Significant Reduction in Rate of Indeterminate Results of the QuantiFERON-TB Gold In-Tube Test by Shortening Incubation Delay. Journal of Clinical Microbiology, 2014, 52, 90-94.	3.9	16
221	Molecular analysis of clinical isolates previously diagnosed as Mycobacterium intracellulare reveals incidental findings of "Mycobacterium indicus pranii―genotypes in human lung infection. BMC Infectious Diseases, 2015, 15, 406.	2.9	16
222	Evaluation of three real-time PCR assays for differential identification of Mycobacterium tuberculosis complex and nontuberculous mycobacteria species in liquid culture media. Diagnostic Microbiology and Infectious Disease, 2016, 85, 186-191.	1.8	16
223	Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea. Journal of Antimicrobial Chemotherapy, 2018, 73, 503-508.	3.0	16
224	Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using) Tj ETQq0 0	0 rgBT /Ov	verlock 10 Tf 5
225	open-label clinical trial. Trials, 2019, 20, 57.  Genome-wide association study in patients with pulmonary <i>Mycobacterium avium</i> complex disease. European Respiratory Journal, 2021, 58, 1902269.	6.7	16
226	Allergic Bronchopulmonary Aspergillosis Coupled with Broncholithiasis in a Non-asthmatic Patient. Journal of Korean Medical Science, 2007, 22, 365.	2.5	15
227	Toxocariasis as a cause of new pulmonary infiltrates. International Journal of Tuberculosis and Lung Disease, 2013, 17, 412-417.	1.2	15
228	Performance evaluation of the Xpert MTB/RIF assay according to its clinical application. BMC Infectious Diseases, 2014, 14, 589.	2.9	15
229	First case of nontuberculous mycobacterial lung disease caused by Mycobacterium marseillense in a patient with systemic lupus erythematosus. Diagnostic Microbiology and Infectious Disease, 2014, 79, 355-357.	1.8	15
230	The Significance of Sensitive Interferon Gamma Release Assays for Diagnosis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonist Therapy. PLoS ONE, 2015, 10, e0141033.	2.5	15
231	Chronic obstructive pulmonary disease severity is associated with severe pneumonia. Annals of Thoracic Medicine, 2015, 10, 105.	1.8	15
232	Effect of Rifampin and Rifabutin on Serum Itraconazole Levels in Patients with Chronic Pulmonary Aspergillosis and Coexisting Nontuberculous Mycobacterial Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 663-665.	3.2	15
233	Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
234	Partial interferon-Î <sup>3</sup> receptor deficiency and non-tuberculous mycobacterial lung disease. Tuberculosis, 2006, 86, 382-385.	1.9	14

#	Article	IF	Citations
235	Clinical characteristics and feasibility of thoracoscopic approach for congenital cystic adenomatoid malformation in adults. European Journal of Cardio-thoracic Surgery, 2007, 31, 797-801.	1.4	14
236	Clinical Application of the Natural Y Stent in the Management of Benign Carinal Stenosis. Annals of Thoracic Surgery, 2009, 88, 432-439.	1.3	14
237	Heterogeneous Spectrum of <i>CFTR</i> Gene Mutations in Korean Patients with Cystic Fibrosis. Annals of Laboratory Medicine, 2011, 31, 219-224.	2.5	14
238	Relationship Between Forced Vital Capacity and Framingham Cardiovascular Risk Score Beyond the Presence of Metabolic Syndrome. Medicine (United States), 2015, 94, e2089.	1.0	14
239	Mycobacterium tuberculosis MmsA, a novel immunostimulatory antigen, induces dendritic cell activation and promotes Th1 cell-type immune responses. Cellular Immunology, 2015, 298, 115-125.	3.0	14
240	Synthetic investigational new drugs for the treatment of tuberculosis. Expert Opinion on Investigational Drugs, 2016, 25, 183-193.	4.1	14
241	Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. Expert Review of Respiratory Medicine, 2019, 13, 851-861.	2.5	14
242	First Case of Disseminated <i>Mycobacterium bolletii</i> Infection in a Young Adult Patient. Journal of Clinical Microbiology, 2009, 47, 3362-3366.	3.9	13
243	HLA Antigens and Nontuberculous Mycobacterial Lung Disease in Korean Patients. Lung, 2009, 187, 136-140.	3.3	13
244	Clinical significance of Mycobacterium szulgai isolates from respiratory specimens. Scandinavian Journal of Infectious Diseases, 2014, 46, 169-174.	1.5	13
245	Essential Engagement of Toll-Like Receptor 2 in Initiation of Early Protective Th1 Response against Rough Variants of Mycobacterium abscessus. Infection and Immunity, 2015, 83, 1556-1567.	2.2	13
246	Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. Chest, 2021, 160, 436-445.	0.8	13
247	Experimental Reactivation of Pulmonary Mycobacterium avium Complex Infection in a Modified Cornell-Like Murine Model. PLoS ONE, 2015, 10, e0139251.	2.5	13
248	Prognostic factors for bronchoscopic intervention in advanced lung or esophageal cancer patients with malignant airway obstruction. Annals of Thoracic Medicine, 2013, 8, 86.	1.8	12
249	Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Expert Opinion on Pharmacotherapy, 2015, 16, 253-261.	1.8	12
250	Assessment of Vitamin Status in Patients with Nontuberculous Mycobacterial Pulmonary Disease: Potential Role of Vitamin A as a Risk Factor. Nutrients, 2019, 11, 343.	4.1	12
251	Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Respiratory Medicine, 2019, 148, 37-42.	2.9	12
252	Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis. BMC Infectious Diseases, 2020, 20, 81.	2.9	12

#	Article	IF	Citations
253	Comparative evaluation of the AdvanSure Mycobacteria GenoBlot assay and the GenoType Mycobacterium CM/AS assay for the identification of non-tuberculous mycobacteria. Journal of Medical Microbiology, 2016, 65, 1422-1428.	1.8	12
254	Association of ISMav6 with the Pattern of Antibiotic Resistance in Korean Mycobacterium avium Clinical Isolates but No Relevance between Their Genotypes and Clinical Features. PLoS ONE, 2016, 11, e0148917.	2.5	12
255	Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication. PLoS ONE, 2017, 12, e0169775.	2.5	12
256	A Practical Protocol for Titrating "Optimal" PEEP in Acute Lung Injury: Recruitment Maneuver and PEEP Decrement. Journal of Korean Medical Science, 2003, 18, 349.	2.5	11
257	Polymorphisms of interferon- $\hat{I}^3$ and interferon- $\hat{I}^3$ receptor 1 genes and non-tuberculous mycobacterial lung diseases. Tuberculosis, 2007, 87, 166-171.	1.9	11
258	Serum Vascular Endothelial Growth Factor and Angiopoietin-2 Are Associated with the Severity of Systemic Inflammation Rather than the Presence of Hemoptysis in Patients with Inflammatory Lung Disease. Yonsei Medical Journal, 2012, 53, 369.	2.2	11
259	Species Distribution and Macrolide Susceptibility of <i>Mycobacterium fortuitum</i> Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
260	Changes in the Flow-Volume Curve According to the Degree of Stenosis in Patients With Unilateral Main Bronchial Stenosis. Clinical and Experimental Otorhinolaryngology, 2015, 8, 161.	2.1	11
261	Treatment of Nontuberculous Mycobacterial Pulmonary Diseases. Tuberculosis and Respiratory Diseases, 2004, 56, 5.	0.2	10
262	Mycobacterium abscessus Pulmonary Infection Presenting as a Solitary Pulmonary Nodule. Internal Medicine, 2006, 45, 169-171.	0.7	10
263	Two Methods of Setting Positive End-expiratory Pressure in Acute Lung Injury: An Experimental Computed Tomography Volumetric Study. Journal of Korean Medical Science, 2007, 22, 476.	2.5	10
264	Interleukin-12 Receptor $\hat{I}^21$ Polymorphisms and Nontuberculous Mycobacterial Lung Diseases. Lung, 2008, 186, 241.	3.3	10
265	A Prospective Study on the Incidence and Predictive Factors of Relative Adrenal Insufficiency in Korean Critically-III Patients. Journal of Korean Medical Science, 2009, 24, 668.	2.5	10
266	Successful Treatment of Mycobacterium celatum Pulmonary Disease in an Immunocompetent Patient Using Antimicobacterial Chemotherapy and Combined Pulmonary Resection. Yonsei Medical Journal, 2010, 51, 980.	2.2	10
267	Impaired Expression of MAPK Is Associated with the Downregulation of TNF-α, IL-6, and IL-10 inMycobacterium abscessusLung Disease. Tuberculosis and Respiratory Diseases, 2012, 72, 275.	1.8	10
268	COPD assessment test score and serum C-reactive protein level in stable COPD patients. International Journal of COPD, 2016, Volume 11, 3137-3143.	2.3	10
269	Clinical significance of smear positivity for acid-fast bacilli after ≥5 months of treatment in patients with drug-susceptible pulmonary tuberculosis. Medicine (United States), 2016, 95, e4540.	1.0	10
270	Different histological subtypes of peripheral lung cancer based on emphysema distribution in patients with both airflow limitation and CT-determined emphysema. Lung Cancer, 2017, 104, 106-110.	2.0	10

#	Article	IF	Citations
271	Changes in Serum IgA Antibody Levels against the Glycopeptidolipid Core Antigen during Antibiotic Treatment of <i>Mycobacterium avium</i> Complex Lung Disease. Japanese Journal of Infectious Diseases, 2017, 70, 582-585.	1.2	10
272	Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolates. Diagnostic Microbiology and Infectious Disease, 2019, 94, 38-40.	1.8	10
273	Basal Serum Cortisol Levels are not Predictive of Response to Corticotropin but Have Prognostic Significance in Patients with Septic Shock. Journal of Korean Medical Science, 2007, 22, 470.	2.5	9
274	Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis-authors' response. Journal of Antimicrobial Chemotherapy, 2009, 64, 1119-1120.	3.0	9
275	First Case of Segniliparus rotundus Pneumonia in a Patient with Bronchiectasis. Journal of Clinical Microbiology, 2011, 49, 3403-3405.	3.9	9
276	Serodiagnostic Potential of Mycobacterium avium MAV2054 and MAV5183 Proteins. Vaccine Journal, 2013, 20, 295-301.	3.1	9
277	The relationships between tracheal index and lung volume parameters in mild-to-moderate COPD. European Journal of Radiology, 2013, 82, e867-e872.	2.6	9
278	Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study. Journal of Korean Medical Science, 2013, 28, 466.	2.5	9
279	Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium lentiflavumin a Patient with Bronchiectasis. Tuberculosis and Respiratory Diseases, 2013, 74, 187.	1.8	9
280	Comparison of Severe Healthcare-Associated Pneumonia with Severe Community-Acquired Pneumonia. Lung, 2014, 192, 313-320.	3.3	9
281	Fibrotic airway stenosis following radiotherapy in patients with adenoid cystic carcinoma. Respirology, 2014, 19, 914-920.	2.3	9
282	Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?. Korean Journal of Internal Medicine, 2016, 31, 15-29.	1.7	9
283	Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
284	18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Treatment Response of Pulmonary Multidrug-Resistant Tuberculosis. Journal of Clinical Medicine, 2018, 7, 559.	2.4	9
285	Naturally-Occurring Polymorphisms in QcrB Are Responsible for Resistance to Telacebec in <i>Mycobacterium abscessus</i> . ACS Infectious Diseases, 2019, 5, 2055-2060.	3.8	9
286	Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. European Respiratory Journal, 2022, 59, 2102950.	6.7	9
287	Usefulness of PCR Test forM. tuberculosisfor the Differentiation of Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease in Patients with Smear-Positive Sputum. Tuberculosis and Respiratory Diseases, 2004, 57, 528.	1.8	8
288	Leukocytoclastic Vasculitis Associated with Macrolide Antibiotics. Internal Medicine, 2008, 47, 1157-1158.	0.7	8

#	Article	IF	CITATIONS
289	Treatment of Latent Tuberculosis Infection in Korea. Tuberculosis and Respiratory Diseases, 2008, 65, 79.	1.8	8
290	Comparison of Clinical and Radiographic Characteristics between Nodular Bronchiectatic Form of Nontuberculous Mycobacterial Lung Disease and Diffuse Panbronchiolitis. Journal of Korean Medical Science, 2009, 24, 427.	2.5	8
291	Pulmonary sequestration infected with nontuberculous mycobacteria: a report of two cases and literature review. Asian Pacific Journal of Tropical Medicine, 2012, 5, 917-919.	0.8	8
292	Tuberculous Lymphadenitis of the Thorax: Comparisons of Imaging Findings Between Patients With and Those Without HIV Infection. American Journal of Roentgenology, 2012, 199, 1234-1240.	2.2	8
293	<scp>EGFR</scp> and <scp>KRAS</scp> mutation analyses from specimens obtained by bronchoscopy and <scp>EBUSâ€₹BNA</scp> . Thoracic Cancer, 2013, 4, 264-272.	1.9	8
294	CT and microbiologic follow-up in primary multidrug-resistant pulmonary tuberculosis. Acta Radiologica, 2016, 57, 197-204.	1.1	8
295	Global Epidemiology of NTM Disease (Except Northern America). Respiratory Medicine, 2019, , 163-260.	0.1	8
296	Treatment Outcomes and Prognostic Factors in Patients with Multidrug-Resistant Tuberculosis in Korean Private Hospitals. Tuberculosis and Respiratory Diseases, 2010, 69, 95.	1.8	8
297	Concurrent Endobronchial Carcinoid Tumor and Sarcoidosis. Internal Medicine, 2010, 49, 2609-2612.	0.7	7
298	Prognostic Significance of Different Subgroup Classifications of Critical Illness-Related Corticosteroid Insufficiency in Patients With Septic Shock. Shock, 2011, 36, 345-349.	2.1	7
299	Normalization of Elevated CA 19-9 Level after Treatment in a Patient with the Nodular Bronchiectatic Form of <i>Mycobacterium abscessus </i> Lung Disease. Tuberculosis and Respiratory Diseases, 2013, 75, 25.	1.8	7
300	A Case of Pleural Paragonimiasis Confused with Tuberculous Pleurisy. Tuberculosis and Respiratory Diseases, 2014, 76, 175.	1.8	7
301	Risk Factors for Acquiring Potentially Drug-Resistant Pathogens in Immunocompetent Patients with Pneumonia Developed Out of Hospital. Respiration, 2014, 88, 190-198.	2.6	7
302	Bronchiectasis and Recurrent Respiratory Infections with a <i>De Novo STAT1</i> Gain-of-Function Variant: First Case in Korea. Yonsei Medical Journal, 2018, 59, 1004.	2.2	7
303	Impact of treatment duration on recurrence of chronic pulmonary aspergillosis. Journal of Infection, 2021, 83, 490-495.	3.3	7
304	Differential Immune Responses to Segniliparus rotundus and Segniliparus rugosus Infection and Analysis of Their Comparative Virulence Profiles. PLoS ONE, 2013, 8, e59646.	2.5	7
305	Multidrug-Resistant Tuberculous Mediastinal Lymphadenitis, with an Esophagomediastinal Fistula, Mimicking an Esophageal Submucosal Tumor. Clinical Endoscopy, 2016, 49, 564-569.	1.5	7
306	In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease. Journal of Clinical Medicine, 2021, 10, 4581.	2.4	7

#	Article	IF	Citations
307	Mycobacterium avium Complex Lung Disease and Panhypopituitarism. Mayo Clinic Proceedings, 2005, 80, 961-962.	3.0	6
308	Two cases of Endobronchial Neurilemmoma and Review of the Literature in Korea. Tuberculosis and Respiratory Diseases, 2007, 62, 129.	1.8	6
309	Bronchoscopic Findings of Pulmonary Paragonimiasis. Tuberculosis and Respiratory Diseases, 2009, 67, 512.	1.8	6
310	Induction of macrophage death by clinical strains of Mycobacterium kansasii. Microbial Pathogenesis, 2010, 48, 160-167.	2.9	6
311	Poor correlation between tuberculin skin tests and interferonâ€Î³ assays in close contacts of patients with multidrugâ€resistant tuberculosis. Respirology, 2012, 17, 1125-1130.	2.3	6
312	Tracheal Wall Thickening Is Associated with the Granulation Tissue Formation Around Silicone Stents in Patients with Post-Tuberculosis Tracheal Stenosis. Yonsei Medical Journal, 2013, 54, 949.	2.2	6
313	Broncho-Pleural Fistula with Hydropneumothorax at CT: Diagnostic Implications in <i>Mycobacterium avium</i> Complex Lung Disease with Pleural Involvement. Korean Journal of Radiology, 2016, 17, 295.	3.4	6
314	Clinical Utility of Additional Measurement of Total Lung Capacity in Diagnosing Obstructive Lung Disease in Subjects With Restrictive Pattern of Spirometry. Respiratory Care, 2016, 61, 475-482.	1.6	6
315	Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. European Respiratory Journal, 2019, 53, 1801636.	6.7	6
316	Diagnostic Performance of the GENEDIA MTB/NTM Detection Kit for Detecting <i>Mycobacterium tuberculosis</i> and Nontuberculous Mycobacteria With Sputum Specimens. Annals of Laboratory Medicine, 2020, 40, 169-173.	2.5	6
317	<i>Mycobacterium avium</i> lung disease combined with a bronchogenic cyst in an immunocompetent young adult. Korean Journal of Internal Medicine, 2013, 28, 94.	1.7	6
318	Solitary Pulmonary Nodule due to Mycobacterium intracellulare: The First Case in Korea. Yonsei Medical Journal, 2007, 48, 127.	2.2	5
319	The Value of Routinely Culturing for Tuberculosis During Bronchoscopies in an Intermediate Tuberculosis-Burden Country. Yonsei Medical Journal, 2007, 48, 969.	2.2	5
320	Diagnosis and treatment of nontuberculous mycobacterial lung disease. Journal of the Korean Medical Association, 2011, 54, 1053.	0.3	5
321	Additional role of second washing specimen obtained during single bronchoscopy session in diagnosis of pulmonary tuberculosis. BMC Infectious Diseases, 2013, 13, 404.	2.9	5
322	Nontuberculous Mycobacterial Lung Disease Caused by <i>Mycobacterium shinjukuense</i> : The First Reported Case in Korea. Tuberculosis and Respiratory Diseases, 2015, 78, 416.	1.8	5
323	Effect of a 150Âmg dose of rifabutin on serum itraconazole levels in patients with coexisting chronic pulmonary aspergillosis and Mycobacterium avium complex lung disease. Journal of Infection and Chemotherapy, 2017, 23, 658-660.	1.7	5
324	Additional role of bronchial mucosal biopsy for ciliary structural abnormality in diagnosis of primary ciliary dyskinesia. Journal of Thoracic Disease, 2019, 11, 839-847.	1.4	5

#	Article	IF	CITATIONS
325	Nontuberculous Mycobacterial Lung Disease Caused by <i>Mycobacterium chelonae </i> Tuberculosis and Respiratory Diseases, 2013, 74, 191.	1.8	4
326	Nontuberculous Mycobacterial Lung Disease Caused by <i>Mycobacterium simiae </i> Reported Case in South Korea. Tuberculosis and Respiratory Diseases, 2015, 78, 432.	1.8	4
327	Isolated EndobronchialMycobacterium aviumDisease Associated with Lobar Atelectasis in an Immunocompetent Young Adult: A Case Report and Literature Review. Tuberculosis and Respiratory Diseases, 2015, 78, 412.	1.8	4
328	Nontuberculous Mycobacteria-Overview., 2017,, 653-661.		4
329	In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, Including Macrolideand Amikacin-Resistant Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	4
330	<i>In Vitro</i> Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, e0230620.	3.2	4
331	Pulmonary Disease Caused by Mycobacterium xenopi: The First Case in Korea. Yonsei Medical Journal, 2007, 48, 871.	2.2	4
332	Treatment of <i>Mycobacterium abscessus</i> Pulmonary Disease. Korean Journal of Medicine, 2019, 94, 343-352.	0.3	4
333	Histopathologic Diagnosis of Pleural Metastasis of Renal Cell Carcinoma Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Tuberculosis and Respiratory Diseases, 2011, 71, 355.	1.8	4
334	Hepatitis C Virus Infection and Isoniazid Hepatotoxicity. Chest, 2007, 132, 736-737.	0.8	3
335	Clarithromycin Susceptibility Testing of Mycobacterium avium Complex Using 2,3-Diphenyl-5-thienyl-(2)-tetrazolium Chloride Microplate Assay with Middlebrook 7H9 Broth. Journal of Korean Medical Science, 2009, 24, 511.	2.5	3
336	Predictors of developing acute respiratory distress syndrome in patients with miliary tuberculosis [Editorial]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 995-995.	1.2	3
337	The First Korean Case of Nontuberculous Mycobacterial Lung Disease Caused by <i>Mycobacterium abscessus </i> Subspecies <i>bolletii </i> in a Patient with Bronchiectasis. Tuberculosis and Respiratory Diseases, 2014, 76, 30.	1.8	3
338	Distinguishing between pulmonary tuberculosis and non-tuberculous mycobacterial lung disease. International Journal of Tuberculosis and Lung Disease, 2014, 18, 633-633.	1.2	3
339	First Isolation of <i>Mycobacterium virginiense</i> From a Human Pulmonary Specimen. Annals of Laboratory Medicine, 2019, 39, 596-598.	2.5	3
340	Efficacy of Long-term Interferon-alpha Therapy in Adult Patients with Recurrent Respiratory Papillomatosis. Tuberculosis and Respiratory Diseases, 2008, 65, 390.	1.8	3
341	The Utility of MAGE Gene Detection in Bronchial Washing Fluid for Patients with Peripheral NSCLC. Tuberculosis and Respiratory Diseases, 2008, 64, 15.	1.8	2
342	A Case of Tracheal Capillary Hemangioma in an Adult. Tuberculosis and Respiratory Diseases, 2010, 69, 385.	1.8	2

#	Article	IF	CITATIONS
343	Evaluation of MolecuTech Real MTB-ID for MTB/NTM Detection Using Direct Specimens. Taehan Imsang Misaengmul Hakhoe Chi = Korean Journal of Clinical Microbiology, 2011, 14, 103.	0.5	2
344	First Case of Pulmonary Disease Caused by a Mycobacterium avium Complex Strain of Presumed Veterinary Origin in an Adult Human Patient. Journal of Clinical Microbiology, 2013, 51, 1993-1995.	3.9	2
345	<i>Mycobacterium abscessus</i> Lung Disease in a Patient with Kartagener Syndrome. Tuberculosis and Respiratory Diseases, 2014, 77, 136.	1.8	2
346	Changes in QT intervals after azithromycin-containing antibiotic therapy in patients with NTM lung disease. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1385-1385.	1.2	2
347	MDR-TB recurrence after successful treatment: additional studies using molecular genotyping are needed. International Journal of Tuberculosis and Lung Disease, 2015, 19, 371-371.	1.2	2
348	The Complex Association of Metabolic Syndrome and Its Components with Computed Tomography–Determined Emphysema Index. Metabolic Syndrome and Related Disorders, 2015, 13, 132-139.	1.3	2
349	Performance evaluation of the Cobas TaqMan MTB assay on respiratory specimens according to clinical application. International Journal of Infectious Diseases, 2017, 64, 42-46.	3.3	2
350	Advantages of the AdvanSure MDR-TB GenoBlot assay containing disputed rpoB mutation-specific probes in a routine clinical laboratory setting. Respiratory Medicine, 2019, 146, 71-75.	2.9	2
351	Genetic Analysis of Korean Adult Patients with Nontuberculous Mycobacteria Suspected of Primary Ciliary Dyskinesia Using Whole Exome Sequencing. Yonsei Medical Journal, 2021, 62, 224.	2.2	2
352	Nontuberculous Mycobacterial Lung Disease. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2006, 49, 806.	0.1	2
353	Accuracy of Spirometry at Predicting Restrictive Pulmonary Impairment. Tuberculosis and Respiratory Diseases, 2003, 54, 330.	0.2	1
354	Postbronchoscopy Fever in Patients With Nontuberculous Mycobacterial Lung Disease. Chest, 2005, 127, 2287-2288.	0.8	1
355	Sarcoidosis with an Endobronchial Mass. Internal Medicine, 2007, 46, 1271-1272.	0.7	1
356	Multicystic Pulmonary Parenchymal Lesions in a Young Adult with Hemoptysis. Tuberculosis and Respiratory Diseases, 2007, 62, 71.	1.8	1
357	Clinical Significance Of Differentiation Between Mycobacterium Abscessus And Mycobacterium Massiliense., 2010,,.		1
358	The role of pleural fluid MAGE RTâ€nested PCR in the diagnosis of malignant pleural effusion. Thoracic Cancer, 2012, 3, 320-325.	1.9	1
359	Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium terraein a Patient with Bronchiectasis. Tuberculosis and Respiratory Diseases, 2012, 72, 173.	1.8	1
360	Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease. Tuberculosis and Respiratory Diseases, 2017, 80, 153.	1.8	1

#	Article	IF	CITATIONS
361	The Prognostic Utility of the Simplified Acute Physiology Score II (SAPS II) and the Sequential Organ Failure Assessment (SOFA) Score for Hemato-Oncology Patients Admitted to the Intensive Care Unit. The Korean Journal of Critical Care Medicine, 2009, 24, 4.	0.2	1
362	Usefulness of Photodynamic Therapy in the Management of Early Central Lung Cancer: A Report of Three Cases. Tuberculosis and Respiratory Diseases, 2009, 67, 338.	1.8	1
363	Management of Patients With Relapsing Polychondritis and Airway Complications. Journal of Bronchology, 2005, 12, 14-19.	0.2	0
364	ACUTE EXACERBATION OF NONSPECIFIC INTERSTITIAL PNEUMONIA. Chest, 2007, 132, 429A.	0.8	0
365	Successful Treatment of Mycobacterium fortuitum Lung Disease with Oral Antibiotic Therapy: a Case Report. Tuberculosis and Respiratory Diseases, 2008, 64, 293.	1.8	0
366	Pulmonary Paragonimiasis: A Profile Of Patients Diagnosed In A Tertiary Referral Center In Korea. , 2010, , .		0
367	Angiopoietin-2 Is Depended On Hypoxia And Severity Of Lung Inflammation Rather Than The Presence Of Hemoptysis In Inflammatory Lung Disease. , 2010, , .		O
368	A Case of Middle Mediastinal Malignant Paraganglioma. Tuberculosis and Respiratory Diseases, 2011, 70, 165.	1.8	0
369	Timing Of Low-Dose Steroid Therapy In The Management Of Septic Shock. , 2011, , .		O
370	Reply: Drug Concentration Monitoring in Mycobacterium avium Lung Disease: Problems with Methods and Conclusions. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 555-556.	5.6	0
371	Clinical, Laboratory, and Microbiological Differences Between Polymorphonuclear- and Lymphocyte-Dominant TB Pleurisy. Chest, 2016, 150, 565A.	0.8	0
372	Reply: "Letter to the Editor Re: Oh J., et al. Nutrients 2019, 11, 343― Nutrients, 2019, 11, 668.	4.1	0
373	Diagnosis of pulmonary tuberculosis. Journal of the Korean Medical Association, 2019, 62, 18.	0.3	O
374	Computed tomographic findings of macrolide-resistant Mycobacterium massiliense pulmonary disease and changes after antibiotic treatment. Medicine (United States), 2019, 98, e16826.	1.0	0
375	Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?. European Respiratory Journal, 2019, 54, 1901806.	6.7	O
376	Association of p53 Expression with Metabolic Features of Stage I Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2011, 71, 417.	1.8	0
377	A Case ofMycobacterium abscessusLung Disease in a Patient with Cystic Fibrosis. Korean Journal of Medicine, 2015, 88, 74.	0.3	0
378	Treatment outcomes of macrolide-resistantmycobacterium aviumcomplex lung disease. , 2016, , .		0

#	Article	IF	CITATIONS
379	Mycobacterium shimoidei Pulmonary Disease: The First Case in Korea. Laboratory Medicine Online, 2019, 9, 166.	0.2	O